TRUE NEAR-PATIENT TESTING FOR NEONATE, CHILDREN AND ADULTS

Our true near-patient testing GD40 solution best meets the needs of blood glucose monitoring and management in primary care, neonatal care, child nursery, nursing homes for elderly care, decentralized testing, clinics and healthcare centers.

FORA GD40 offers an ultimate platform for accurate, fast and reliable true near-patient blood glucose level monitoring. Apply and test your sample with a touch of assurance of averting from false start, testing error and unnecessary waste of strip.

✓ High accuracy with GDH-FAD strip technology
✓ Wide use with 0-70% hematocrit range
✓ Success increase in testing with strip feed light
✓ Easy-to-read with LCD backlight
✓ Hygiene with strip ejection
✓ Reliable approval with clinically validated by IDT (Institute for Diabetes Technology GmbH) in Germany

IMPROVED PATIENT CARE

Immediate diagnostic results generated from near-patient testing often lead to better patient compliance with their medication and
insulin therapy regimes. Diabetes mellitus is well known as a lifestyle disease. A lifetime commitment to good self-diabetes
management is essential in maintaining near-normal glycemia and lowering risks of diabetic complications. Performing blood
glucose monitoring in front of the patient and having direct face-to-face guidance about suggested changes often result in an
immediate positive impact on patient compliance.

Furthermore, near-patient testing also helps improve the care standards, result turnaround time, staff efficiency, and the overall
effectiveness of diabetes management.

FULL CONTROL IN THE PALM OF YOUR HANDS

True near-patient testing means on-the-go testing regardless of the type of patient.

In other words, it means:
● no interference from various hematocrit
● no interference from various sample types
● no interference from non-glucose sugars that may be present in patients blood samples

Performance Beyond Expectation As Proven

The international standard, ISO 15197:2013, requires that at least 95% of the results from blood glucose meters should be within 15% of laboratory results when equal to or above 100 mg/dL and within 15 mg/dL when below 100 mg/dL.  A clinical study done in May 2014 was conducted by the Institute for Diabetes-Technology (IDT) at the University of Ulm in Germany, FORA GD40 BGM system is evaluated with three reagent system lots and compared with Cobas Integra® 400 Plus glucose analyzer as the reference system. The report indicates that 100% of the results from samples < 100mg/dL (5.55mmol/L) fall within ±15 mg/dL (±0.83 mmol/L) criteria while 98% from samples > 100 mg/dL (5.55 mmol/L) fall within ±15 % criteria.

A: Clinically accurate
B: Deviating from the reference method by more than 15% but would lead to benign or no treatment
C: Deviating from the reference method by more than 15% and would lead to unnecessary corrective treatment errors
D: Potentially dangerous failure to detect and treat blood glucose levels outside of desired target range
E: Resulting in erroneous treatment

With complete confidence in its clinical accuracy, you can now optimize your patient’s medication and/or insulin treatment and improve diabetes care and treatment outcomes through patient counseling, education and communication.

For inquiries about this product:

Tel Nos.: +63 2 7906 0520
Mobile: +63 977 806 0520
Email: info@tsmc.ph

Our Location:
TSMC GF KAVI Building,
193 E. Rodriguez Jr. Ave.
Bagumbayan Libis,
Quezon City 1110
Philippines